(NASDAQ:WBTN), LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) — WEBTOON Entertainment Inc. (Nasdaq: WBTN) (“WEBTOON Entertainment” or “the Company”), a leading global entertainment company and home to some of the world's largest storytelling platforms, today announced CFO and COO, David J. Lee, will participate in the following upcoming investor conferences: J.P. Morgan 13th Global TMT […]

HORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, and Kaken Pharmaceutical Co., Ltd. (“Kaken”), an R&D driven pharmaceutical company in Japan, today announced a strategic licensing and co-development agreement for NM81, a potential first-in-class multispecific

Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock Series C round was supported by both existing and new investors Hennigsdorf/Berlin, November 13, 2025 – 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) today announced the extension of its Series C financing to EUR55 million ($64 million), with participation from existing and new

Prescription Drug User Fee Act (PDUFA) goal date set for August 28, 2026 Garching / Munich, Germany, November 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) completed its filing review and accepted the company's New Drug Application (NDA) for

Xunlei Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2025 GlobeNewswire November 13, 2025 SHENZHEN, China, Nov. 13, 2025 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (Nasdaq: XNET), a leading technology company providing distributed cloud services in China, today announced its unaudited financial results for the third quarter ended September

John Crane launches Performance Plus(TM) – a new era in service excellence for rotating equipment Modern service framework helps industrial operators cut downtime, boost reliability, and accelerate progress towards sustainability goals GlobeNewswire November 13, 2025 SLOUGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) — John Crane, a global leader in rotating equipment solutions and a

Numab Therapeutics and Kaken Pharmaceutical Announce Licensing and Co-development Agreement for Multispecific Antibody NM81 in Inflammatory Bowel Disease (IBD) Kaken Pharmaceutical in-licenses NM81 across select Asian territories and commits to funding global development into the clinic GlobeNewswire November 13, 2025 HORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Numab Therapeutics AG (“Numab”), a

4TEEN4 Extends Series C Financing Round to EUR55 Million, Supporting Expanded Clinical Development of Procizumab in Cardiogenic Shock GlobeNewswire November 13, 2025 Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock Series C round was supported by both existing and new investors Hennigsdorf/Berlin, November 13, 2025 – 4TEEN4 Pharmaceuticals

ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) GlobeNewswire November 13, 2025 Prescription Drug User Fee Act (PDUFA) goal date set for August 28, 2026 Garching / Munich, Germany, November 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical

Bilibili Inc. Announces Third Quarter 2025 Financial Results GlobeNewswire November 13, 2025 SHANGHAI, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced its unaudited financial results for the third quarter ended September